RLFTF News and Press, Mondobiotech Holding AG Basel From 12/14/22

GENEVA, SWITZERLAND / ACCESSWIRE / December 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, r...

Relief Therapeutics ( OTCQB:RLFTY ) said on Tuesday its board of directors approved an increase of its share capital from 4.62B to 5.62 shares. The company issued 1B shares from its authorized capital. The new shares are fully subscribed at par value by the Company's wholly owned ...

GENEVA, SWITZERLAND / ACCESSWIRE / December 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare ...

GENEVA, SWITZERLAND / ACCESSWIRE / November 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ult...

Switzerland-based Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTD ) said it filed an amendment to its registration statement with the U.S. Securities and Exchange Commission (SEC) related to its planned IPO on Nasdaq. The company has proposed a offering of its o...

GENEVA, SWITZERLAND / ACCESSWIRE / November 16, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) ("Relief"), announced today that it has filed Amendment No. 1 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exch...

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (" Relief "), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (" NRx Pharmaceuticals "), today announced that they have entered into definitive settlemen...

Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTD ) and NRx Pharmaceuticals ( NASDAQ: NRXP ) extended the stay of their pending litigation until Nov. 11 to get more time to finalize a settlement. The companies have been embroiled in litigation over experimental...

GENEVA, SWITZERLAND / ACCESSWIRE / November 8, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) (" Relief "), today announced that they and NRx Pharmaceuticals, Inc. (" NRx ") have further extended the stay of their pending litigation until November 11, 2022. While t...

Relief Therapeutics ( OTCQB:RLFTF )( OTCQB:RLFTD ) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil). The company said the data showed high purity levels at six months at all temperatures tested, including a...